Cargando…

Monoclonal antibodies binding to different epitopes of CD20 differentially sensitize DLBCL to different classes of chemotherapy

INTRODUCTION: Rituximab (R), an anti-CD20 monoclonal antibody (mAb) and the world’s first approved antibody for oncology patients, was combined with the CHOP chemotherapy regimen and markedly improved the prognosis of all B- cell–derived lymphomas, the most common hematological malignancy worldwide....

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Brian, Pierpont, Tim, August, Avery, Richards, Kristy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436104/ https://www.ncbi.nlm.nih.gov/pubmed/37601699 http://dx.doi.org/10.3389/fonc.2023.1159484

Ejemplares similares

Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
por: Pierpont, Timothy M., et al.
Publicado: (2018)

Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk
por: Lyu, Cuicui, et al.
Publicado: (2021)

The Tumor Microenvironment of DLBCL in the Computational Era
por: Opinto, Giuseppina, et al.
Publicado: (2020)

Treating Early-Stage DLBCL on the FLYER: What Lesson for Radiation Therapy?
por: Sokol, Kelsey, et al.
Publicado: (2021)

The immune checkpoint expression in the tumor immune microenvironment of DLBCL: Clinicopathologic features and prognosis
por: Ma, Jiajia, et al.
Publicado: (2022)

The Role of Different Supplements in Expression Level of Monoclonal Antibody against Human CD20
por: Mahboudi, Fereidoun, et al.
Publicado: (2013)

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
por: van der Horst, Hilma J., et al.
Publicado: (2021)

Monoclonal antibodies targeting CD20
por: Chang, Chien-Hsing, et al.
Publicado: (2013)

Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters
por: Ritter, Zsombor, et al.
Publicado: (2022)

A bone-based 3D scaffold as an in-vitro model of microenvironment–DLBCL lymphoma cell interaction
por: Ceccato, Jessica, et al.
Publicado: (2022)

Characterization of a Novel Monoclonal Antibody (27H2) Recognizing Human CD34 Class III Epitope
por: Hong, Kwon Pyo, et al.
Publicado: (2010)

A human monoclonal antibody bivalently binding two different epitopes in streptococcal M protein mediates immune function
por: Bahnan, Wael, et al.
Publicado: (2022)

CCND2 mRNA Expression Is Correlated With R-CHOP Treatment Efficacy and Prognosis in Patients With ABC-DLBCL
por: Wang, Di, et al.
Publicado: (2020)

Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series
por: Zhang, Yan, et al.
Publicado: (2021)

A diagnostic scoring model of ENKTCL in the nose-Waldeyer’s ring based on logistic regression: Differential diagnosis from DLBCL
por: Xiang, Jun-Yi, et al.
Publicado: (2023)

Response to: Monoclonal antibodies targeting CD20
por: Klein, Christian, et al.
Publicado: (2013)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

High Therapeutic Efficacy of a New Survivin LSP-Cancer Vaccine Containing CD4(+) and CD8(+) T-Cell Epitopes
por: Onodi, Fanny, et al.
Publicado: (2018)

The Roles of IRF-8 in Regulating IL-9-Mediated Immunologic Mechanisms in the Development of DLBCL: A State-of-the-Art Literature Review
por: Cai, Mingyue, et al.
Publicado: (2022)

CD5 and CD43 Expression are Associate with Poor Prognosis in DLBCL Patients
por: Huang, Hui, et al.
Publicado: (2018)

DLBCL developed into fatal liver failure during rituximab-containing chemotherapy
por: Shimazu, Yutaka, et al.
Publicado: (2019)

Glutaminolysis Mediated by MALT1 Protease Activity Facilitates PD-L1 Expression on ABC-DLBCL Cells and Contributes to Their Immune Evasion
por: Xia, Xichun, et al.
Publicado: (2018)

The Effects of Different Induction Chemotherapy Cycles and Adjuvant Chemotherapy on the Survival Outcomes of Patients With Locally Advanced Nasopharyngeal Carcinoma
por: Liao, Shu, et al.
Publicado: (2022)

Differences in the outcomes of adjuvant chemotherapy for colon cancer prescribed by physicians in different disciplines: a population-based study in Taiwan
por: Hsieh, Cheng-I, et al.
Publicado: (2018)

Case Report: CD19 and CD20 monoclonal antibodies with sequential chemotherapy for refractory acute B-lymphocytic leukemia in children
por: Li, Jia-Nan, et al.
Publicado: (2023)

CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells
por: Jiang, Shuang, et al.
Publicado: (2016)

Novel CD20 monoclonal antibodies for lymphoma therapy
por: Cang, Shundong, et al.
Publicado: (2012)

Treatment Outcome of Different Chemotherapy in Patients With Relapsed or Metastatic Malignant Urachal Tumor
por: Chen, Meiting, et al.
Publicado: (2021)

Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA)--implications for targeted therapy.
por: Boxer, G. M., et al.
Publicado: (1994)

Antigenic Analysis of Monoclonal Antibodies against Different Epitopes of σB Protein of Avian Reovirus
por: Yin, Chun-hong, et al.
Publicado: (2013)

Check'-ing DLBCL
por: Salaverria, Itziar, et al.
Publicado: (2015)

DLBCL Coast to Coast
por: Tesio, Melania
Publicado: (2018)

GOALs in relapsed DLBCL
por: Rösler, Wiebke, et al.
Publicado: (2022)

Expression and clinical significance of CD31, CD34, and CD105 in pulmonary ground glass nodules with different vascular manifestations on CT
por: Guo, Chen-ran, et al.
Publicado: (2022)

Predictors and Long-Term Outcomes for Diffuse Large B-Cell Lymphoma (DLBCL) Patients Undergoing Surgery Prior to Systemic Therapy: A Nationwide Analysis
por: Vusqa, Urwat, et al.
Publicado: (2022)

Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-κB and initiates tumour vascular normalization
por: Gan, Hui K, et al.
Publicado: (2009)

Commentary: Treatment Outcome of Different Chemotherapy in Patients With Relapsed or Metastatic Malignant Urachal Tumor
por: Szarvas, Tibor, et al.
Publicado: (2022)

Ofatumumab: a novel monoclonal anti-CD20 antibody
por: Lin, Thomas S
Publicado: (2010)

Anti-CD20 monoclonal antibodies: reviewing a revolution
por: Casan, J. M. L., et al.
Publicado: (2018)

Identification of epitopes associated with different biological activities on the glycoprotein of vesicular stomatitis virus by use of monoclonal antibodies
por: Nagata, S., et al.
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_t6a7ba3lla4hk411guv5s53dsu